Primary malignant melanoma of the penis: a case report

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

J M Kirkwood, M H Strawderman, Marc S. Ernstoff et al. · Journal of Clinical Oncology · 1996 · 2.1K citations

Medicine, Oncology, Pharmacotherapy +17

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak et al. · Journal of Clinical Oncology · 2000 · 922 citations

Pharmacy, Oncology, Pharmacotherapy +15

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

John M. Kirkwood, Joseph G. Ibrahim, Jeffrey A. Sosman et al. · Journal of Clinical Oncology · 2001 · 907 citations · Full text

Medicine, Immunology, Oncology +17

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

Hubert Pehamberger, H. Peter Soyer, Andreas Steiner et al. · Journal of Clinical Oncology · 1998 · 360 citations

Medicine, Oncology, Surgery +17

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Alexander M.M. Eggermont, Stefan Suciu, Rona M. MacKie et al. · The Lancet · 2005 · 315 citations

Medicine, Oncology, Surgery +17